Security key
10501E201
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI)
CUSIP: 10501E201
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / COM NEW
- Total 13F shares
- 10,822,351
- Total 13F value
- $2,486,573
- Share change
- -1,258,888
- Put/Call ratio
- 19%
- SEC-reported price per share
- $0.23
- Number of holders
- 33
- Value change
- -$330,765
- Number of buys
- 7
- Number of sells
- 21
Open additional details 1 more signal available
Report period
Q3 2024
Institutions
33
Top holders
10
BCLI full security history
Ownership snapshot
Full 13F holder table
BRAINSTORM CELL THERAPEUTICS INC. SEC filings
BRAINSTORM CELL THERAPEUTICS INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of BCLI - BRAINSTORM CELL THERAPEUTICS - COM NEW (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sankesh Abbhi
Disclosed value leader
Sankesh Abbhi
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5
13F
Highest disclosed value: $3,860,181
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Sankesh Abbhi has the largest disclosed position value at $3.86M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sankesh Abbhi's linked filing trail.
Disclosed position value
Top 5
Sankesh Abbhi
$3.86M
ARMISTICE CAPITAL, LLC
$2.68M
VANGUARD GROUP INC
$511.4K
Ralph Dr. Kern
$396.2K
GEODE CAPITAL MANAGEMENT, LLC
$164K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sankesh Abbhi |
3/4/5
Director
|
—
class O/S missing
|
$3,860,181
2,175,853 shares
|
— | 10 Dec 2021 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
—
class O/S missing
|
$2,680,126
7,917,653 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
—
class O/S missing
|
$511,352
1,510,640 shares
|
— | 30 Jun 2024 |
| Ralph Dr. Kern |
3/4/5
COO and Chief Medical Officer
|
—
class O/S missing
|
$396,174
223,310 shares
|
— | 06 Mar 2022 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$163,986
484,285 shares
|
— | 30 Jun 2024 |
| Malcolm S. Taub |
3/4/5
Director
|
—
class O/S missing
|
$137,195
77,332 shares
|
— | 15 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
10,822,351
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
44
Q3 2024 holders
33
Holder diff
-11
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|